Home > Publications Database > PKR stirs up inflammasomes. > print

001     136817
005     20240321220136.0
024 7 _ |a 10.1038/cr.2012.125
|2 doi
024 7 _ |a pmid:22945351
|2 pmid
024 7 _ |a pmc:PMC3567816
|2 pmc
024 7 _ |a 1001-0602
|2 ISSN
024 7 _ |a 1748-7838
|2 ISSN
037 _ _ |a DZNE-2020-03139
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Stunden, H James
|0 P:(DE-HGF)0
|b 0
245 _ _ |a PKR stirs up inflammasomes.
260 _ _ |a [London]
|c 2013
|b Macmillan Publishers Limited, part of Springer Nature
264 _ 1 |3 online
|2 Crossref
|b Springer Science and Business Media LLC
|c 2012-09-04
264 _ 1 |3 print
|2 Crossref
|b Springer Science and Business Media LLC
|c 2013-02-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1593434008_12122
|2 PUB:(DE-HGF)
|x Editorial
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Inflammasomes are multiprotein complexes that detect and respond to foreign and endogenous danger signals by activating caspase-1; active caspase-1, in turn, matures the pro-inflammatory IL-1β family cytokines by cleaving their pro-forms into the biologically active cytokines. The upstream mechanisms leading to inflammasome activation, in particular for the NRLP3 inflammasome, remain poorly understood. Lu and colleagues identify a new function of Protein Kinase R (PKR) for activating the NLRP1, NLRP3, NLRC4 and AIM2 inflammasomes, thus identifying a potential new target for treating inflammasome-mediated diseases.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
542 _ _ |i 2012-09-04
|2 Crossref
|u http://www.springer.com/tdm
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Carrier Proteins
|2 NLM Chemicals
650 _ 7 |a Inflammasomes
|2 NLM Chemicals
650 _ 7 |a NLR Family, Pyrin Domain-Containing 3 Protein
|2 NLM Chemicals
650 _ 7 |a Nlrp3 protein, mouse
|2 NLM Chemicals
650 _ 7 |a Nitric Oxide
|0 31C4KY9ESH
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Carrier Proteins: metabolism
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Inflammasomes: metabolism
|2 MeSH
650 _ 2 |a NLR Family, Pyrin Domain-Containing 3 Protein
|2 MeSH
650 _ 2 |a Nitric Oxide: metabolism
|2 MeSH
650 _ 2 |a Shock, Septic: prevention & control
|2 MeSH
700 1 _ |a Latz, Eicke
|0 P:(DE-2719)2000062
|b 1
|e Last author
|u dzne
773 1 8 |a 10.1038/cr.2012.125
|b : Springer Science and Business Media LLC, 2012-09-04
|n 2
|p 168-170
|3 journal-article
|2 Crossref
|t Cell Research
|v 23
|y 2012
|x 1001-0602
773 _ _ |a 10.1038/cr.2012.125
|g Vol. 23, no. 2, p. 168 - 170
|0 PERI:(DE-600)2082402-6
|n 2
|q 23:2<168 - 170
|p 168-170
|t Cell research
|v 23
|y 2012
|x 1001-0602
856 7 _ |2 Pubmed Central
|u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567816
909 C O |o oai:pub.dzne.de:136817
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2000062
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|2 G:(DE-HGF)POF3-300
|v Disease Mechanisms and Model Systems
|x 0
914 1 _ |y 2013
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL RES : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b CELL RES : 2017
920 1 _ |0 I:(DE-2719)1013024
|k AG Latz
|l Innate Immunity in Neurodegeneration
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1013024
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.1016/j.coi.2009.12.004
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.coi.2009.12.004
999 C 5 |a 10.1146/annurev-immunol-030409-101323
|9 -- missing cx lookup --
|2 Crossref
|o 10.1146/annurev-immunol-030409-101323
999 C 5 |a 10.1111/j.1600-065X.2011.01042.x
|9 -- missing cx lookup --
|2 Crossref
|o 10.1111/j.1600-065X.2011.01042.x
999 C 5 |a 10.1038/nature11290
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/nature11290
999 C 5 |a 10.1038/nri2314
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/nri2314
999 C 5 |a 10.1016/j.immuni.2012.02.020
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.immuni.2012.02.020
999 C 5 |a 10.1016/j.cell.2005.06.041
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.cell.2005.06.041
999 C 5 |a 10.1016/j.cell.2005.06.044
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.cell.2005.06.044
999 C 5 |a 10.1038/nature02405
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/nature02405
999 C 5 |a 10.1016/j.cell.2010.01.001
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.cell.2010.01.001
999 C 5 |a 10.1016/j.cell.2010.01.040
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.cell.2010.01.040
999 C 5 |a 10.1083/jcb.200711082
|9 -- missing cx lookup --
|2 Crossref
|o 10.1083/jcb.200711082

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21